469 related articles for article (PubMed ID: 33402214)
1. The management of metastatic GIST: current standard and investigational therapeutics.
Kelly CM; Gutierrez Sainz L; Chi P
J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
3. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
[TBL] [Abstract][Full Text] [Related]
5. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Naito Y; Nishida T; Doi T
Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
[TBL] [Abstract][Full Text] [Related]
6. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
7. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
9. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumor - A review of clinical studies.
Khoshnood A
J Oncol Pharm Pract; 2019 Sep; 25(6):1473-1485. PubMed ID: 31068088
[TBL] [Abstract][Full Text] [Related]
12. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
13. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
14. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
[TBL] [Abstract][Full Text] [Related]
15. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
16. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
Yonkus JA; Alva-Ruiz R; Grotz TE
Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
Vadakara J; von Mehren M
Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
[TBL] [Abstract][Full Text] [Related]
18. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
19. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
20. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
Khosroyani HM; Klug LR; Heinrich MC
Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
